5,5'-Dicarboxy-2,2'-bipyridine
Based on 1 Customer Validation
5,5'-Dicarboxy-2,2'-bipyridine is a niacin derivative, which is promising for research of hypercholesterolemia, hyperlipidemia, and cardiovascular disease.
For research use only. We do not sell to patients.
- Purity : 99.76%
- CAS No.: 1802-30-8
- Formula: C12H8N2O4
- Molecular Weight:244.20
-
Storage:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-D0020
2,2'-BipyridineMetal Chelating Ligand -
HY-W004545
6,6'-Dimethyl-2,2'-bipyridylMetal-organic Framework -
HY-W004578
2,2'-Bipyridine-6,6'-dicarboxylic AcidMetal-organic Framework -
![[2,2'-Bipyridine]-3,3'-dicarboxylic acid](https://file.medchemexpress.com/product_pic/hy-w004579.gif)
HY-W004579
[2,2'-Bipyridine]-3,3'-dicarboxylic acidMetal-organic Framework -
HY-W004544
o-PhenanthrolineMMP Inhibitor -
HY-W004576
6-Bromo-2,2'-bipyridylMetal-organic Framework -
HY-W004547
(NH2)2bpyBiochemical Assay Reagent -
HY-W004546
AbametapirMetalloproteinase Inhibitor -
HY-W002003
4,4'-Dimethyl-2,2'-bipyridineBiochemical Reagent -
HY-W004762
MeO-bpyMetal-organic Framework -
![Dimethyl [2,2'-bipyridine]-4,4'-dicarboxylate](https://file.medchemexpress.com/product_pic/hy-w004589.gif)
HY-W004589
Dimethyl [2,2'-bipyridine]-4,4'-dicarboxylateDrug Intermediate -
![[2,2'-Bipyridine]-4,4'-diyldimethanol](https://file.medchemexpress.com/product_pic/hy-w004569.gif)
HY-W004569
[2,2'-Bipyridine]-4,4'-diyldimethanolMetal-organic Framework
Biological Activity
Description
Chemical Information
-
CAS No. 1802-30-8
-
Appearance Solid
-
Molecular Weight 244.20
-
Formula C12H8N2O4
-
Color Off-white to gray
-
SMILES
O=C(C1=CN=C(C2=NC=C(C(O)=O)C=C2)C=C1)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
In Vitro:
DMSO : 2 mg/mL (8.19 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0950 mL | 20.4750 mL | 40.9500 mL | 102.3751 mL |
| 5 mM | 0.8190 mL | 4.0950 mL | 8.1900 mL | 20.4750 mL |
5,5'-Dicarboxy-2,2'-bipyridine Related Classifications
HY-W004580 Related Classifications
Powered by Bioz